ACERCA DE DC BEAD™
DC Bead™ is used in transarterial chemoembolisation (TACE). This is a minimally invasive (non-surgical) procedure performed by an interventional radiologist.
DC Bead™ is an embolic Drug-eluting bead capable of loading and releasing chemotherapeutic agents in a controlled manner.
It is produced from a biocompatible polyvinyl alcohol (PVA) hydrogel that has been modified with sulphonate groups for the controlled loading and delivery of chemotherapeutic drugs.
DC Bead™ occludes the blood flow to the target tissue and delivers a local and sustained dose of drug direct to the tumour.
The product is tinted blue for easy visualisation and is supplied in colour coded vials for added procedural safety and efficiency.
DC Bead™ was developed to offer several benefits in the treatment of TACE:
- Reproducible drug loading8,9,11
- Consistent drug elution 11,13
- Reduction in side effect1,6
- Standardised treatment recommendations1,4
- Improvement in survival outcomes2,3
- DC Bead™is a drug eluting bead that has loading of doxorubicin within its CE Marked indication statement1
- The benefits of DC Bead™ are supported by over 150 peer reviewed papers and are now recognised in the European Clinical Practice Guidelines for HCC4,5
- FIRST DEBDOX™ with DC Bead™: Expert Panel Technical Recommendations (HCC)1,4
- FIRST Five-year Survival Data (HCC)2
Drug-Eluting Bead: DEBDOX™
DC Bead™ and DC BeadM1™ are compatible with doxorubicin for the local treatment of tumours in patients with hepatocellular carcinoma (HCC). Doxorubicin can be loaded prior to embolisation and as a secondary action, will elute a local, controlled and sustained dose to the tumour after embolisation.
Drug-Eluting Bead: DEBIRI™
DC Bead™ and DC BeadM1™ can be loaded prior to embolisation and then as a secondary action, elute a local, controlled and sustained dose to the liver metastases from colorectal cancer after embolisation.
DC Bead™ is CE-Mark approved for loading with doxorubicin (DEBDOX™) and irinotecan (DEBIRI™) .
INDICACIONES:
DC Bead™ and DC BeadM1™ are primarily intended as an embolic agent for the local treatment of malignant hypervascularised tumour(s) in the liver.
DC Bead™ and DC BeadM1™ are compatible with doxorubicin for the local treatment of tumours in patients with hepatocellular carcinoma (HCC).
Doxorubicin can be loaded prior to embolisation and as a secondary action, will elute a local, controlled and sustained dose to the tumour after embolisation.
DC Bead™ and DC BeadM1™ are also intended to embolise the vessels supplying malignant colorectal cancer metastasised to the liver (mCRC).
DC Bead™ and DC BeadM1™ are compatible with irinotecan which can be loaded prior to embolisation and then as a secondary action, elute a local, controlled and sustained dose to the liver metastases from colorectal cancer after embolisation.
